Sunday, July 12 – (MedPage Today) — Variable weight-loss and cardiovascular benefits were seen with GLP-1 drugs in a systematic review and network meta-analysis, but effects on quality of life were less clear.
Across 262 randomized studies published through November…

Friday, July 10 – (MedPage Today) — Analysis of hundreds of thousands of patient records showed differing risks for autoimmune disorders for new users of the more recent types of antidiabetic medications.
Rates of new-onset autoimmune conditions were compared…

Friday, July 10 – The share of U.S. adults taking GLP-1 medications to lose weight has reached a record 11%.

Friday, July 10 – Obesity and dietitian societies have joined forces to issue a new consensus statement on recommendations surrounding the use of obesity drugs for weight loss treatment. The statement, which is published in The Lancet Diabetes & Endocrinology, is led by Dr. Laurence Dobbie of the Department of Population Health Sciences, King’s College London, with an international team of 26 authors.

Friday, July 10 – Medicare prescriptions for Wegovy increased sharply after the program started covering the anti-obesity medication to prevent heart problems, but just a fraction of beneficiaries likely eligible received the treatment, according to new research published in the American Journal of Managed Care by the USC Schaeffer Center for Health Policy & Economics.

Friday, July 10 – (MedPage Today) — Diabetes patients with hepatocellular carcinoma (HCC) experienced longer time to HCC recurrence and longer survival when they initiated a GLP-1 agonist rather than a DPP-4 inhibitor, a target trial emulation study found. (Gut…

Thursday, July 9 – Poison control calls involving semaglutide (Ozempic and Wegovy) soared after the drug was approved for weight management, with researchers linking the increase to accidental dosing mistakes rather than intentional misuse. Simple education about proper weekly dosing and gradual dose increases could help prevent many of these avoidable incidents.

Thursday, July 9 – (MedPage Today) — Americans’ use of GLP-1 injectables for weight loss reached a record high, nearly quadrupling since 2024, according to a national Gallup poll.
For patients with type 2 diabetes and peripheral artery disease, GLP-1 receptor agonists…

Thursday, July 9 – The new Medicare GLP-1 Bridge program offers broader, more affordable access to weight loss drugs to address the growing obesity crisis. But there’s a catch when it comes to bone health.

Thursday, July 9 – Getting a GLP-1 prescription online can be quick and convenient, but new research suggests it may come with surprisingly little medical oversight. The findings are published in the journal JAMA.

Thursday, July 9 – New data on Hengrui Pharma and Kailera Therapeutics’ investigational oral GLP-1 have validated the late-stage weight loss asset and paved the road for a regulatory submission in China, but analysts pointed to high rates of nausea and vomiting that could challenge the ongoing U.S. study.

Wednesday, July 8 – Survodutide weight-loss drug may reduce harmful fat while preserving muscle

Wednesday, July 8 – AstraZeneca’s new oral GLP-1 pill showed promising results for weight loss and blood sugar in a phase 2 trial. Guido Mieth/Getty Images

A new GLP-1 oral medication from AstraZeneca, known as elecoglipron, lowered blood sugar levels and led to 10.5% weight loss in a phase 2b clinical trial.

Experts say GLP-1 drugs in tablet form may encourage more people to take these medications to help treat type 2 diabetes and obesity.

Wednesday, July 8 – A new once-daily weight-loss pill called orforglipron delivered better weight loss and blood sugar improvements for people with type 2 diabetes than the leading oral semaglutide in a major clinical trial. The tablet could offer a more convenient alternative to injectable drugs like Ozempic and Wegovy because it doesn’t require refrigeration or special timing with meals. It’s also cheaper to manufacture, which could expand access globally.

Tuesday, July 7 – Federal regulators have agreed to review a Swiss pharmaceutical company’s applications for two cheaper generic versions of Zepbound and Mounjaro. MK Photo/Alamy Stock Photo

Federal regulators have agreed to review the applications from Swiss pharmaceutical company Sandoz for two cheaper generic versions of the tirzepatide medications Zepbound and Mounjaro.

Tuesday, July 7 – (MedPage Today) — Two-thirds of online GLP-1 receptor agonist sellers did not require speaking with a clinician ahead of a prescription, a secret shopper study revealed.
Out of 49 websites tested, 13 required a video visit and three required…

Tuesday, July 7 – (MedPage Today) — At the American Diabetes Association annual meeting, results from the ACHIEVE-5 trial showed that adding oral orforglipron (Foundayo) to basal insulin significantly improved glycemic control, reduced body weight, and limited…

Saturday, July 4 – On June 16, 2026, the US Food and Drug Administration (FDA) issued 25 warning letters to various telehealth companies alleging that their websites contained false or misleading claims about compounded semaglutide, tirzepatide, and, in one case, liraglutide products….By: McDermott Will & Schulte

Tuesday, May 19 – Semaglutide for Weight Loss Without Diabetes: What the Approval Covers, What Programs Skip, and What Results Actually Look Like